TNF Inhibitors Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 39.67 Billion |
| Market Size (2029) | USD 47.32 Billion |
| CAGR (2024 - 2029) | 3.59 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
TNF Inhibitors Market Analysis
The TNF Inhibitors Market size is estimated at USD 39.67 billion in 2024, and is expected to reach USD 47.32 billion by 2029, growing at a CAGR of 3.59% during the forecast period (2024-2029).
COVID-19 had an unprecedented impact on the market's growth due to disruption in the supply chain across the globe. TNF inhibitors found large applications in the treatment of COVID-19, thereby impacting the demand. For instance, the Journal of American Medical Association article published in October 2021 concluded that TNF inhibitor monotherapy was associated with a lower risk of adverse COVID-19 outcomes compared with other commonly prescribed immunomodulatory treatment regimens among individuals with immune-mediated inflammatory diseases. Thus, studies that demonstrate the effectiveness of the TNF monotherapy treatment in COVID-19 patients had a significant impact on the growth of the market. In addition, the demand for TNF inhibitors during the post-pandemic period is expected to remain intact due to the emergence of various mutant strains of the SARS-CoV-2 virus and the rising focus on auto-immune disease treatments, thereby contributing to the growth of the market over the forecast period.
The major factors attributing to the growth of the market are the rise in the global prevalence of autoimmune disorders such as (RA) Rheumatoid Arthritis, Inflammatory Bowel Disorder, Psoriasis, and Crohn's disease coupled with the increase in the aged population. For instance, As per the International Foundation for Gastrointestinal Disorders (IFFGD) report published in 2021, around 10 to 15% of the population is affected by irritable bowel syndrome worldwide, including approximately 25 to 45 million people suffering from the disease in the United States. Also, according to a report by the CDC published on World IBD Day in April 2021, the number of people affected by IBD was around 7 million worldwide annually. The report also stated that the rate of prevalence of the disease significantly increased during the last two decades. Such increasing incidences of various auto-immune diseases are expected to drive the demand for effective treatment and therapeutics such as TNF inhibitors, thereby contributing to the market's growth over the forecast period.
Furthermore, the approval of the products by the regulatory authorities to provide safe and effective therapeutics also contributes to the market's growth. For Instance, in December 2021, Coherus BioSciences, Inc. received United States FDA approval for YUSIMRY (adalimumab-aqvh), formerly CHS-1420, a Humira (adalimumab) biosimilar product. YUSIMRY is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
Thus, owing to the abovementioned factors, the market is anticipated to project growth over the forecast period. However, the high risk of complications coupled with challenges while in the development stage and expensive patented biologics may hinder the market's growth.
TNF Inhibitors Market Trends
Rheumatoid Arthritis Segment Is Expected to Project Large Growth Over the Forecast Period
Rheumatoid Arthritis (RA) is an autoimmune condition in which the immune system of the own body attacks the healthy tissues of the body. Biologic drugs work by targeting proteins called cytokines, which are responsible for the inflammation caused by the immune system's response. In the case of 'anti-TNF' drugs, the cytokines being targeted are known as 'TNF' (TumourNecrosis Factor alpha). The factors such as the growing burden of RA disease, approval of drugs by the regulatory authority, and the launch of products by the market players are propelling the growth of the market segment over the forecast period.
The growing burden of rheumatoid arthritis is largely propelling the growth of the market segment. According to the Global RA Network report 2021, more than 350 million people were living with arthritis around the world in 2021, and its burden is expected to increase owing to various factors, one of which is the rising burden of the geriatric population around the globe. Such a high prevalence of rheumatoid arthritis is also boosting the growth of the studied market.
Additionally, the approval of drugs by different regulatory authorities of the region and the launch of products is expected to drive the growth of the studied segment. For instance, in March 2021, Samsung Bioepis launched its adalimumab biosimilar Hadlima in Australia in partnership with Merck & Co. Hadlima is approved for the treatment of rheumatoid arthritis and other indications in Australia. Such launch of anti-TNF biosimilars for the treatment of rheumatoid arthritis is propelling the growth of the market segment.
Thus, owing to the abovementioned factors, the market segment is expected to project significant growth over the forecast period.
North America is Expected to Witness a Growth in the Market Over the Forecast Period
North America is expected to hold a major market share in the overall TNF inhibitors market throughout the forecast period. The dominance is expected due to several factors, such as well-established direct reimbursement policies and the availability of advanced healthcare infrastructure in the region.
The growing burden of autoimmune diseases in different countries worldwide is also propelling the market's growth. For instance, in 2022, the Crohns and Colitis Foundation report mentioned that Crohn's disease and ulcerative colitis affected 1.6 million Americans, most of whom are aged before 35. Similarly, the Government Statistics Canada data published in August 2022, the number of arthritis in Canada in 2021 was 6,087,600. Such a high prevalence of autoimmune disorders in North American countries is expected to drive the demand for effective therapeutics, thereby boosting the market growth in this region.
Also, the accelerating product approval procedure by regulatory authorities in North America is expected to propel the market's growth in the region. For instance, in February 2022, Pfizer Inc. received United States Food and Drug Administration (FDA) acceptance for review of the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA (adalimumab-AFB) as an interchangeable biosimilar to Humira (adalimumab).
Thus, owing to the abovementioned factors, such as the rising prevalence of autoimmune disorders and the presence of key market players along with frequent product launches, the North American region is expected to show lucrative growth over the forecast period.
TNF Inhibitors Industry Overview
The TNF Inhibitors Market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some prominent players are acquiring other companies to consolidate their market positions across the globe and while others are launching new products. Some companies currently dominating the market are Abbvie Inc, Pfizer Inc, Johnson & Johnson, Amgen Inc, and UCB Inc.
TNF Inhibitors Market Leaders
-
UCB Inc
-
Pfizer Inc
-
Johnson & Johnson
-
Amgen Inc.
-
Abbvie
*Disclaimer: Major Players sorted in no particular order
TNF Inhibitors Market News
- July 2022: Sandoz received the United States Food and Drug Administration (FDA) acceptance for review of its Supplemental Biologics License Application (sBLA) for a high concentration formulation of 100 mg/mL (HCF) of its biosimilar Hyrimoz (adalimumab-adaz).
- February 2022: MyMD Pharmaceuticals Inc. introduced Phase 1 clinical trial data demonstrating MYMD-1's reduction of tumor necrosis factor-alpha (TNF-α), the molecules that are the root cause of aging, in the blood of healthy human subjects.
TNF Inhibitors Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Global Prevalence of Autoimmune Disorders and Rise in Geriatric Popuation
- 4.2.2 New Product Launches of Biosimilars with Accelerated Drug Approval Initiative by USFDA
-
4.3 Market Restraints
- 4.3.1 High Risk of Complications such as Heart Failure, Liver Injury, Neurological Disorders, Psoriasis and Many Allergic Reactions
- 4.3.2 High Challenges while in the Development Stage and Expensive Patented Biologics
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Drug Class
- 5.1.1 Adalimumab
- 5.1.2 Infliximab
- 5.1.3 Rituximab
- 5.1.4 Others
-
5.2 By Indication
- 5.2.1 Rheumatoid Arthritis
- 5.2.2 Crohn's Disease
- 5.2.3 Psoriasis
- 5.2.4 Others
-
5.3 By End-user
- 5.3.1 Hospital Pharmacies
- 5.3.2 Specialty Pharmacies
- 5.3.3 Online Pharmacies
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 UCB Inc
- 6.1.2 Pfizer Inc
- 6.1.3 Amgen Inc
- 6.1.4 AbbVie Inc
- 6.1.5 Johnson & Johnson
- 6.1.6 F. Hoffmann-La Roche AG
- 6.1.7 Boehringer Ingelheim Pharmaceuticals
- 6.1.8 Novartis International AG
- 6.1.9 Merck kGaA
- 6.1.10 Lupin
- 6.1.11 Sanofi
- 6.1.12 Bristol-Myers Squibb Company
- 6.1.13 Cadila Healthcare Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityTNF Inhibitors Industry Segmentation
As per the scope of the report, TNF-alpha is the first element in the cytokine cascade, which plays a vital role in systemic inflammation and is identified as the cause of various autoimmune diseases. TNF inhibitors are drugs that reverse the damage caused by autoimmune diseases.
The TNF Inhibitors Market is segmented by Drug class (Adalimumab, Infliximab, Rituximab, and Others), Indication (Rheumatoid Arthritis, Crohn's Disease, Psoriasis, and Others), End-user (Hospital Pharmacies, Specialty Pharmacies, and Online Pharmacies) Geography (North America, Europe, Asia-Pacific, Middle East, and Africa and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the abovementioned segments.
| By Drug Class | Adalimumab | |
| Infliximab | ||
| Rituximab | ||
| Others | ||
| By Indication | Rheumatoid Arthritis | |
| Crohn's Disease | ||
| Psoriasis | ||
| Others | ||
| By End-user | Hospital Pharmacies | |
| Specialty Pharmacies | ||
| Online Pharmacies | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
TNF Inhibitors Market Research FAQs
How big is the TNF Inhibitors Market?
The TNF Inhibitors Market size is expected to reach USD 39.67 billion in 2024 and grow at a CAGR of 3.59% to reach USD 47.32 billion by 2029.
What is the current TNF Inhibitors Market size?
In 2024, the TNF Inhibitors Market size is expected to reach USD 39.67 billion.
Who are the key players in TNF Inhibitors Market?
UCB Inc, Pfizer Inc, Johnson & Johnson, Amgen Inc. and Abbvie are the major companies operating in the TNF Inhibitors Market.
Which is the fastest growing region in TNF Inhibitors Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in TNF Inhibitors Market?
In 2024, the North America accounts for the largest market share in TNF Inhibitors Market.
What years does this TNF Inhibitors Market cover, and what was the market size in 2023?
In 2023, the TNF Inhibitors Market size was estimated at USD 38.25 billion. The report covers the TNF Inhibitors Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the TNF Inhibitors Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Gauze Bandage Rolls Industry Report
Statistics for the 2024 Gauze Bandage Rolls market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Gauze Bandage Rolls analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
